July 10, 2026 04:36 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Foreign franchise league enters India! BBL opener to be played in Chennai, announce Modi-Albanese | 'They could have stopped me': Vijay blames police, former DMK government over Karur stampede | 'People will correct their 2025 mistake': Electoral debutant Prashant Kishor predicts BJP defeat in Bankipur | New assassination plot against Trump? Israel's secret intelligence raises alarm amid escalating Middle East tension | Ayatollah Ali Khamenei buried at Iran's holiest shrine as Middle East crisis deepens | Indian techie allegedly kills wife in US, sends photo of her body to 'secret girlfriend' in India; arrested | 'I fled the city': Thane doctor quits after alleged assault by Shiv Sena leader | Sensex surges 500 points before losing steam, ends marginally higher after volatile trading session | US court drops charges against Indian-origin doctor who drove Tesla off 250-foot cliff with family | Dalal Street bleeds! Sensex tanks over 1,600 points after Trump declares Iran ceasefire 'over'
Adar Poonawalla
Image credit: Adar Poonawalla Twitter

Vaccine for children above 3 years in next 6 months: Adar Poonawalla

| @indiablooms | Dec 15, 2021, at 01:16 am

New Delhi/UNI: Amid concern over the spread of the Omicron variant of Covid-19 virus and vulnerability of children, Adar Poonawalla, Chief Executive Officer of the Serum Institute of India, on Tuesday said alongwith two other companies, SII has reached the trial phase of developing a vaccine for the children aged above three and it should be ready within the next 6 months.

“In the last 2 years of the pandemic, India is now better prepared to deal with such a catastrophe, and hopefully the worst is behind us all. With over a billion-dollar investment that has gone into developing and manufacturing the Covid-19 vaccine, the journey so far has given us several key lessons owing to the rapidly changing situation in accordance with the mutating virus,” said Poonawalla, at the CII Partnership Summit 2021 organised in association with Department for Promotion of Industry and Internal Trade (DPIIT).

The SII was working towards developing the vaccine booster shot for Omicron virus which is more effective, said Poonawalla.

He apprised that they “On the back of enough data, it is safe to say that booster vaccines are a proven strategy to get antibodies up to a great extent.”

With supply of the vaccines out matching demand globally, to keep up with the momentum, Poonawalla suggested that countries come together and form some agreement in order to prepare standard rules for clinical trials and manufacturing of the vaccines.

The SII CEO pointed out that multilateral organisations and policy makers should be able to identify and isolate the new mutations and find out the efficacy of vaccines against it, in a time bound manner.

The need for greater collaborations and action facilitated by multilateral organisations to be prepared for the COVID situation was also expressed by Ong Ye Kung, Minister for Health, Singapore at the CII Partnership Summit.

As economies like Singapore depend largely on connections with the world and are sustained with seaport and airport infrastructure, the Singapore Government will strive to keep the borders open for business and movement as it learns to live with COVID-19 as an endemic disease, the Minister said.

He suggested skills training and collaborating with India’s IT and healthcare sector as the way forward to further strengthen the India-Singapore relationship on healthcare related matters.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.